Steve Schrodi

Steve received his Ph.D. in Biological Sciences from University of California-Irvine in 2001, where his dissertation was focused on stochastic models of population genetics and molecular evolution.  He was recruited to DNA Sciences where he led a group of computational scientists to build a statistical genetics infrastructure to map disease genes in colon cancer and other diseases using extended kinships from the Utah population.  In addition, he managed a psoriasis gene mapping study.  Subsequently, he was recruited to Celera to where he served in dual scientific roles developing statistical genetics methods and designing/analyzing exome-wide SNP association studies in rheumatoid arthritis, psoriasis, HCV-induced liver fibrosis, neurodegeneration, idiopathic short stature and pharmacogenetics.  He was awarded 10 US Patents and the Applera Demonstrated Noteworthy Achievement Award for his discoveries made at Celera.  Additionally, the Arthritis Foundation cited the PTPN22 finding as one of the top 10 scientific discoveries of 2004.  Following his work at Celera, Steve served as a Principal Investigator at the Marshfield Clinic Research Institute focused on the genetics of chronic inflammatory conditions and metabolic dysfunction as well as theoretical genetics of diseases.                                                                       Steve’s group at UW-Madison in the Laboratory of Genetics is conducting research on models of disease genetics, Bayesian statistical approaches to disease genomics and epigenomics, and mapping genomic regions that confer susceptibility to complex diseases.